Benjamin Derman to Neoplasm, Residual
This is a "connection" page, showing publications Benjamin Derman has written about Neoplasm, Residual.
Connection Strength
3.611
-
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 10 07; 14(1):170.
Score: 0.882
-
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J. 2021 02 05; 11(2):19.
Score: 0.684
-
Clinician attitudes and practices toward measurable residual disease in multiple myeloma. Br J Haematol. 2020 08; 190(3):470-472.
Score: 0.653
-
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood. 2024 08 29; 144(9):955-963.
Score: 0.219
-
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
Score: 0.215
-
Measurable Residual Disease and Decision-Making in Multiple Myeloma. Hematol Oncol Clin North Am. 2024 04; 38(2):477-495.
Score: 0.209
-
MRD-guided treatment cessation in multiple myeloma. Lancet Haematol. 2023 11; 10(11):e867-e868.
Score: 0.205
-
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.
Score: 0.191
-
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma. Blood Cancer J. 2022 07 11; 12(7):108.
Score: 0.189
-
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021 01; 35(1):18-30.
Score: 0.165